Lundbeckfond Invest A/S, CVR21855545, is the Danish investment holding company wholly owned by the legally distinct Lundbeck Foundation, CVR11814913. The foundation’s audited group overview places Strategic Ownerships, Invest financial investments and Lundbeckfonden BioCapital within this company and identifies NMD Pharma as its associate. BioCapital is the internal evergreen biotech venture-investment unit, financing early through clinical-stage science-based companies; EMERGE was its earlier early-stage unit branding, with Christian E. Elling’s EMERGE managing-partner term January2017–March2022 and BioCapital role fromApril2022 documented in an issuer SEC proxy. The holding company’s public investment activities draw on twenty current named operational professionals across BioCapital, Invest and Strategic Ownerships; these are source-qualified unit affiliations rather than inferred separate payroll contracts or corporate directors. Foundation, legal holding company, internal unit brands and manufacturer H. Lundbeck A/S remain distinct. NMD investment participations are represented once under the actual holding-company buyer, with historical EMERGE/BioCapital branding retained in sources. The evergreen strategy uses foundation-owned capital; no external LP final close is inferred from portfolio values, commitments, ownership percentages or yearly investment totals.